Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation

Genes and Development

Volumn 19, Issue 16, 2005, Pages 1934-1950

  List, Karin ^a   Szabo, Roman ^a   Molinolo, Alfredo ^a   Sriuranpong, Virote ^a   Redeye, Vivien ^a   Murdock, Tricia ^a   Burke, Beth ^a   Nielsen, Boye S ^b   Gutkind, J Silvio ^a   Bugge, Thomas H ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Carcinoma; Cell surface protease; Multistage carcinogenesis; Oncogenic proteolysis; Ras; Transmembrane serine protease

Indexed keywords

RAS PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DYSPLASIA; EPIDERMIS CELL; EPITHELIUM CELL; GENE CONTROL; GENE EXPRESSION; HYPERPLASIA; MOUSE; NONHUMAN; ONCOGENE; OVARY FOLLICLE CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMIS; HUMANS; LYMPH NODES; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; PROTEIN KINASE C; RAS PROTEINS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

MUS MUSCULUS;

EID: 23944489424     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1300705     Document Type: Article

References (52)

1. Amornphimoltham, P., Sriuranpong, V., Patel, V., Benavides, F., Conti, C.J., Sauk, J., Sausville, E.A., Molinolo, A.A., and Gutkind, J.S. 2004. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: A potential target for UCN-01. Clin. Cancer Res. 10: 4029-4037.
2. Balmain, A. 1985. Transforming ras oncogenes and multistage carcinogenesis. Br. J. Cancer 51: 1-7.
3. Balmain, A. and Pragnell, I.B. 1983. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303: 72-74.
4. Benaud, C.M., Oberst, M., Dickson, R.B., and Lin, C.Y. 2002. Deregulated activation of matriptase in breast cancer cells. Clin. Exp. Metastasis 19: 639-649.
5. Bhatt, A.S., Takeuchi, T., Ylstra, B., Ginzinger, D., Albertson, D., Shuman, M.A., and Craik, C.S. 2003. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 384: 257-266.
6. Bolon, I., Zhou, H.M., Charron, Y., Wohlwend, A., and Vassalli, J.D. 2004. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am. J. Pathol. 164: 2299-2304.
7. Chang, C. and Werb, Z. 2001. The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends. Cell Biol. 11: S37-S43.
8. Cho, E.G, Kim, M.G., Kim, C., Kim, S.R., Seong, I.S., Chung, C., Schwartz, R.H., and Park, D. 2001. N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease. J. Biol. Chem. 276: 44581-44589.
9. Coussens, L.M. and Werb, Z. 2002. Inflammation and cancer. Nature 420: 860-867.
10. Dano, K., Romer, J., Nielsen, B.S., Bjorn, S., Pyke, C., Rygaard, J., and Lund, L.R. 1999. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types. Apmis 107: 120-127.
11. Engelholm, L.H., Nielsen, B.S., Netzel-Arnett, S., Solberg, H., Chen, X.D., Lopez Garcia, J.M., Lopez-Otin, C., Young, M.F., Birkedal-Hansen, H., Dano, K., et al. 2001. The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloprotease-13 during osteogenesis. Lab. Invest. 81: 1403-1414.
12. Galkin, A.V., Mullen, L., Fox, W.D., Brown, J., Duncan, D., Moreno, O., Madison, E.L., and Agus, D.B. 2004. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 61: 228.
13. Hennings, H., Glick, A.B., Lowry, D.T., Krsmanovic, L.S., Sly, L.M., and Yuspa, S.H. 1993. FVB/N mice: An inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14: 2353-2358.
14. Hoang, C.D., D'Cunha, J., Kratzke, M.G., Casmey, C.E., Frizelle, S.P., Maddaus, M.A., and Kratzke, R.A. 2004. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125: 1843-1852.
15. Hooper, J.D., Campagnolo, L., Goodarzi, G., Truong, T.N., Stuhlmann, H., and Quigley, J.P. 2003. Mouse matriptase-2: Identification, characterization and comparative mRNA expression analysis with mouse hepsin in adult and embryonic tissues. Biochem. J. 373: 689-702.
16. Hotary, K.B., Allen, E.D., Brooks, P.C., Datta, N.S., Long, M.W., and Weiss, S.J. 2003. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the threedimensional extracellular matrix. Cell 114: 33-45.
17. Ise, K., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., Miyoshi, J., Gondo, Y., Ishikawa, T., Aiba, A., et al. 2000. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19: 2951-2956.
18. Jin, X., Hirosaki, T., Lin, C.Y., Dickson, R.B., Higashi, S., Kitamura, H., and Miyazaki, K. 2005. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J. Cell Biochem. 95: 632-647.
19. Johnson, M.D., Oberst, M.D., Lin, C.Y., and Dickson, R.B. 2003. Possible role of matriptase in the diagnosis of ovarian cancer. Expert. Rev. Mol. Diagn. 3: 331-338.
20. Kang, J.Y., Dolled-Filhart, M., Ocal, I.T., Singh, B., Lin, C.Y., Dickson, R.B., Rimm, D.L., and Camp, R.L. 2003. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63: 1101-1105.
21. Kim, M.G., Chen, C., Lyu, M.S., Cho, E.G., Park, D., Kozak, C., and Schwartz, R.H. 1999. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49: 420-428.
22. Lee, S.L., Dickson, R.B., and Lin, C.Y. 2000. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275: 36720-36725.
23. Lin, C.Y., Anders, J., Johnson, M., Sang, Q.A., and Dickson, R.B. 1999. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274: 18231-18236.
24. List, K., Haudenschild, C.C., Szabo, R., Chen, W., Wahl, S.M., Swaim, W., Engelholm, L.H., Behrendt, N., and Bugge, T.H. 2002. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765-3779.
25. List, K., Szabo, R., Wertz, P.W., Segre, J., Haudenschild, C.C., Kim, S.Y., and Bugge, T.H. 2003. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 163: 901-910.
26. Macfarlane, S.R., Seatter, M.J., Kanke, T., Hunter, G.D., and Plevin, R. 2001. Proteinase-activated receptors. Pharmacol. Rev. 53: 245-282.
27. Matrisian, L.M. 1999. Cancer biology: Extracellular proteinases in malignancy. Curr. Biol. 9: 776-778.
28. McIntyre, J.O. and Matrisian, L.M. 2003. Molecular imaging of proteolytic activity in cancer. J. Cell Biochem. 90: 1087-1097.
29. Murillas, R., Larcher, F., Conti, C.J., Santos, M., Ullrich, A., and Jorcano, J.L. 1995. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14: 5216-5223.
30. Netzel-Arnett, S., Mitola, D.J., Yamada, S.S., Chrysovergis, K., Holmbeck, K., Birkedal-Hansen, H., and Bugge, T.H. 2002. Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity. J. Biol. Chem. 277: 45154-45161.
31. Netzel-Arnett, S., Hooper, J.D., Szabo, R., Madison, E.L., Quigley, J.P., Bugge, T.H., and Antalis, T.M. 2003. Membrane anchored serine proteases: A rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 22: 237-258.
32. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R.B., and Lin, C.Y. 2001. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158: 1301-1311.
33. Oberst, M.D., Johnson, M.D., Dickson, R.B., Lin, C.Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J.F., Gabra, H., et al. 2002. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer. Res. 8: 1101-1107.
34. Orsulic, S., Li, Y., Soslow, R.A., Vitale-Cross, L.A., Gutkind, J.S., and Varmus, H.E. 2002. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1: 53-62.
35. Parr, C. and Jiang, W.G. 2001. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol. 19: 857-863.
36. Quintanilla, M., Brown, K., Ramsden, M., and Balmain, A. 1986. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80.
37. Ramirez, A., Bravo, A., Jorcano, J.L., and Vidal, M. 1994. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 58: 53-64.
38. Santin, A.D., Cane, S., Bellone, S., Bignotti, E., Palmieri, M., De Las Casas, L.E., Anfossi, S., Roman, J.J., O'Brien, T., and Pecorelli, S. 2003. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 98: 1898-1904.
39. Santin, A.D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J.J., et al. 2004. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112: 14-25.
40. Schnack Nielsen, B., Rank, F., Engelholm, L.H., Holm, A., Dano, K., and Behrendt, N. 2002. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int. J. Cancer 98: 656-664.
41. Segrelles, C., Ruiz, S., Perez, P., Murga, C., Santos, M., Budunova, I.V., Martinez, J., Larcher, F., Slaga, T.J., Gutkind, J.S., et al. 2002. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21: 53-64.
42. Sternlicht, M.D., Lochter, A., Sympson, C.J., Huey, B., Rougier, J.P., Gray, J.W., Pinkel, D., Bissell, M.J., and Werb, Z. 1999. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137-146.
43. Suzuki, M., Kobayashi, H., Kanayama, N., Saga, Y., Suzuki, M., Lin, C.Y., Dickson, R.B., and Terao, T. 2004. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound prourokinase. J. Biol. Chem. 279: 14899-14908.
44. Szabo, R., Netzel-Arnett, S., Hobson, J.P., Antalis, T.M., and Bugge, T.H. 2005. Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem. J. 390: 231-240.
45. Takeuchi, T., Shuman, M.A., and Craik, C.S. 1999. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membranetype serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. 96: 11054-11061.
46. Takeuchi, T., Harris, J.L., Huang, W., Yan, K.W., Coughlin, S.R., and Craik, C.S. 2000. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275: 26333-26342.
47. Tanimoto, H., Underwood, L.J., Wang, Y., Shigemasa, K., Parmley, T.H., and O'Brien, T.J. 2001. Ovarian tumor cells express a transmembrane serine protease: A potential candidate for early diagnosis and therapeutic intervention. Tumour Biol. 22: 104-114.
48. Velasco, G., Cal, S., Quesada, V., Sanchez, L.M., and Lopez-Otin, C. 2002. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J. Biol. Chem. 277: 37637-37646.
49. Vivanco, I. and Sawyers, C.L. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501.
50. Wilson, C.L., Heppner, K.J., Labosky, P.A., Hogan, B.L., and Matrisian, L.M. 1997. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. 94: 1402-1407.
51. Yuspa, S.H. 1998. The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis. J. Dermatol. Sci. 17: 1-7.
52. Zhou, H.M., Nichols, A., Meda, P., and Vassalli, J.D. 2000. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J. 19: 4817-4826.